Flexion Therapeutics Stock News

Flexion Therapeutics, Inc. (FLXN) today announced new positive preclinical efficacy and pharmacokinetic (PK) data for FX301, its locally administered peripheral nerve block candidate for control of po

Russo Partners' Sports-Health Alliance, part of the New York City-based healthcare and technology communications firm, has launched "Stay Safe. Stay Together. Stay Healthy," a social media campaign to

In a report released today, Carl Byrnes from Northland Securities maintained a Buy rating on Nabriva (NBRV), with a price target of $2.50. The company's

Northland Securities analyst Carl Byrnes maintained a Buy rating on Zogenix (ZGNX) today and set a price target of $65.00. The company's shares closed

Northland Securities analyst Carl Byrnes maintained a Buy rating on Zogenix ( ZGNX – Research Report ) today and set a price target of $65.00 . The company’s shares closed last Wednesday at $25.99

Flexion Therapeutics (NASDAQ:FLXN) was upgraded by equities research analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wedn

In a report released today, Carl Byrnes from Northland Securities maintained a Buy rating on PolarityTE (PTE), with a price target of $8.00. The company's

In a report released today, Carl Byrnes from Northland Securities maintained a Buy rating on PolarityTE (PTE – Research Report),

Northland Securities analyst Carl Byrnes initiated coverage with a Buy rating on vTv Therapeutics (VTVT) today and set a price target of $8.00. The

Northland Securities analyst Carl Byrnes initiated coverage with a Buy rating on vTv Therapeutics (VTVT – Research Report) today and

Geode Capital Management LLC boosted its holdings in shares of Flexion Therapeutics Inc (NASDAQ:FLXN) by 7.7% during the 4th quarter, according to the company in its most recent disclosure with the SE

Northland Securities analyst Carl Byrnes maintained a Hold rating on Esperion (ESPR) today and set a price target of $42.00. The company's shares closed

Northland Securities analyst Carl Byrnes maintained a Hold rating on Esperion (ESPR – Research Report) today and set a price